A phase 1, multicenter, open label, clinical trial of immune response, safety and tolerability of DNA vector pPRA-PSM with synthetic peptides E-PRA and E-PSM [MKC 1106-PP; MannKind Corporation] in subjects with advanced solid malignancies

Trial Profile

A phase 1, multicenter, open label, clinical trial of immune response, safety and tolerability of DNA vector pPRA-PSM with synthetic peptides E-PRA and E-PSM [MKC 1106-PP; MannKind Corporation] in subjects with advanced solid malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2010

At a glance

  • Drugs MKC 1106 PP (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Aug 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 02 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Oct 2009 Data were presented at the International Society for Biological Therapy of Cancer 2009 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top